摘要
目的:对沈阳地区转移性骨肿瘤住院患者抗肿瘤药物发生不良事件进行药物流行病学调查,为合理使用抗肿瘤药物提供参考依据。方法:采集沈阳地区2004-2014年转移性骨肿瘤住院患者的病历信息,分析其不良事件的基本特征、抗肿瘤药物种类、剂型、器官或系统分布。结果:抗肿瘤药物不良事件发生例数8242例,合计30122例次不良事件,其中男性患者占61.64%,女性患者占38.36%;发生不良事件的患者中,45~64岁患者占47.00%,45岁以上患者占74.99%;发生不良事件的的药物最高的是其他抗肿瘤药物及辅助治疗药,比例为39.91%;发生不良事件的抗肿瘤药物剂型中,注射剂占95.43%;发生不良事件的器官或系统最多的是消化系统,比例为22.63%。结论:沈阳地区转移性骨肿瘤住院患者在使用抗肿瘤药物时应加强45岁以上患者的监护,为明确抗肿瘤药物的监管提供了参考依据。
Objective:To explore the clinical features of drug adverse events in patients with metastatic bone tumor treated with antitumor drug,and to provide scientific basis for rational use of antitumor drug and reduction in the incidence of drug adverse events.Methods:Medical records on metastatic bone tumor were retrospectively collected from 4 hospitals in Shenyang between 2004 and 2014.Data of drug adverse events was analyzed on the characteristics of the patients,classification and pharmaceutical dosage form of antitumor drug,and organs and systems involved.Results:A total of8242 cases of metastatic bone tumors with 30122 drug adverse events were collected from 2004 to 2014.The proportion of male patients was 61.64%,while the proportion of female patients was 38.36%.The proportion was the highest at age from45 to 64 years(47.00%),and the age over 45 years old accounted for 74.99%.The highest proportion of drug classification was other antitumor drugs and adjuvant therapy drugs,which accounted for 39.91%.The highest proportion of pharmaceutical dosage form was injection,which accounted for 95.43%.The highest proportion of organs and systems involved was digestive system,which accounted for 22.63%.Conclusion:The pharmacoepidemiological features of drug adverse events in patients with metastatic bone tumor treated with antitumor drug could promote rational drug use and prevent or reduce the incidence of drug adverse events.
引文
1.Bergovec M,Kubat O,Smerdelj M,et al.Epidemiology of musculoskeletal tumors in a national referral orthopedic department.A study of3482 cases[J].Cancer Epidemiol,2015,39(3):298-302.
2.Duong LM,Richardson LC.Descriptive epidemiology of malignant primary osteosarcoma using population-based registries,United States,1999-2008[J].J Registry Manag,2013,40(2):59-64.
3.Harwood JL,Alexander JH,Mayerson JL,et al.Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma[J].Orthop Clin North Am,2015,46(4):587-608.
4.朱淑平,宫建,孙永发,等.妇产科围手术期患者抗菌药物不良事件调查[J].中国公共卫生,2012,28(12):1660-1661.
5.王海涛,宫建,吴凯,等.抗菌药物致甲状腺疾病手术患者不良事件的临床评价[J].中国医院用药评价与分析,2014,14(5):445-447.
6.于丽娅,刘莉,穆慧娟,等.单纯被动随访评估人群肿瘤生存率偏倚分析[J].中华肿瘤防治杂志,2015,22(6):407-411.
7.王亮,宫建,李福生,等.原发性骨肿瘤患者的临床特征分析[J].中国医学工程,2015:23(10):1-2,4.
8.王亮,宫建,郑刚,等.转移性骨肿瘤患者临床特征的初步分析[J].中国医药指南,2016,14(7):67-68.
9.王亮,宫建,郑刚,等.转移性骨肿瘤患者抗肿瘤药物不良事件分析[J].中国公共卫生,2016,(3):391-393.
10.Fletcher CDM,Bridge JA,Hongendoorn PC,et al.WHO classification of tumours of soft tissue and bone[M].Lyon:IARC Press,2013.
11.王建,宫建,于嵩,等.丙泊酚和异氟醚对老年脑膜瘤患者抗炎疗效分析[J].中国公共卫生,2015,3l(1):120-121.
12.Aydin M,Basarir K,Armangil M,et al.Thermal necrosis induced by electrocauterization as a local adjuvant therapy in local aggressive bone tumors,what is the safe limit for surgical margins?An experimental study[J].Arch Orthop Trauma Surg,2015,135(8):1071-1076.